DDInter576 DDInter1492
A carbamate derivative used as an alcohol deterrent. It is a relatively nontoxic substance when administered alone, but markedly alters the intermediary metabolism of alcohol. When alcohol is ingested after administration of disulfiram, blood acetaldehyde concentrations are increased, followed by flushing, systemic vasodilation, respiratory difficulties, nausea, hypotension, and other symptoms (acetaldehyde syndrome). It acts by inhibiting aldehyde dehydrogenase.
Ponatinib is a novel Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I mutation for the treatment of chronic myeloid leukemia. FDA approved on December 14, 2012.
Disulfiram {u} (Compound) binds {v} (Gene) CYP3A5
CYP3A5 {u} (Gene) is bound by {v} (Compound) Ponatinib
Disulfiram {u} (Compound) upregulates {v} (Gene) SOCS2
SOCS2 {u} (Gene) is upregulated by {v} (Compound) Ponatinib
Disulfiram {u} (Compound) downregulates {v} (Gene) OXA1L
OXA1L {u} (Gene) is downregulated by {v} (Compound) Ponatinib
Disulfiram {u} (Compound) upregulates {v} (Gene) MYC
MYC {u} (Gene) is downregulated by {v} (Compound) Ponatinib
Disulfiram {u} (Compound) causes {v} (Side Effect) Fatigue
Fatigue {u} (Side Effect) is caused by {v} (Compound) Ponatinib
Disulfiram {u} (Compound) binds {v} (Gene) CYP3A5
CYP3A5 {u} (Gene) is regulated by {v} (Gene) IKBKB
IKBKB {u} (Gene) is upregulated by {v} (Compound) Ponatinib
Disulfiram {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Nilotinib
Nilotinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ponatinib
Disulfiram {u} (Compound) upregulates {v} (Gene) SOCS2
SOCS2 {u} (Gene) is upregulated by {v} (Compound) Nilotinib
Nilotinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ponatinib
Disulfiram {u} (Compound) downregulates {v} (Gene) OXA1L
OXA1L {u} (Gene) is regulated by {v} (Gene) RET
RET {u} (Gene) is bound by {v} (Compound) Ponatinib
Disulfiram {u} (Compound) downregulates {v} (Gene) CANT1
CANT1 {u} (Gene) is downregulated by {v} (Compound) Nilotinib
Nilotinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ponatinib
Disulfiram (Compound) binds CYP3A5 (Gene) and CYP3A5 (Gene) is bound by Ponatinib (Compound)
Disulfiram (Compound) upregulates SOCS2 (Gene) and SOCS2 (Gene) is upregulated by Ponatinib (Compound)
Disulfiram (Compound) downregulates OXA1L (Gene) and OXA1L (Gene) is downregulated by Ponatinib (Compound)
Disulfiram (Compound) upregulates MYC (Gene) and MYC (Gene) is downregulated by Ponatinib (Compound)
Disulfiram (Compound) causes Fatigue (Side Effect) and Fatigue (Side Effect) is caused by Ponatinib (Compound)
Disulfiram (Compound) binds CYP3A5 (Gene) and CYP3A5 (Gene) is regulated by IKBKB (Gene) and IKBKB (Gene) is upregulated by Ponatinib (Compound)
Disulfiram (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Nilotinib (Compound) and Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib
Disulfiram (Compound) upregulates SOCS2 (Gene) and SOCS2 (Gene) is upregulated by Nilotinib (Compound) and Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib
Disulfiram (Compound) downregulates OXA1L (Gene) and OXA1L (Gene) is regulated by RET (Gene) and RET (Gene) is bound by Ponatinib (Compound)
Disulfiram (Compound) downregulates CANT1 (Gene) and CANT1 (Gene) is downregulated by Nilotinib (Compound) and Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib